Evidence map›Paper›PMID 34802039›Full record

Trial reportTranslational psychiatry2021

Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia.

Yan Zhang, Han Shi, Ge Yang, Yongfeng Yang, Wenqiang Li, Meng Song, Minglong Shao, Xi Su, Luxian Lv

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. ZnScientific reports · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yan ZhangHenan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Han ShiHenan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Ge YangHenan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Yongfeng YangHenan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Wenqiang LiHenan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.ORCID http://orcid.org/0000-0002-0833-246X
Meng SongHenan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Minglong ShaoHenan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Xi SuHenan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China. suxi198919@163.com.
Luxian LvHenan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China. lvx928@126.com.ORCID http://orcid.org/0000-0002-3963-660X
Henan Psychiatric Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The indoleamine 2,3-dioxygenase (IDO) enzyme is the first rate-limiting enzyme of the tryptophan degradation pathway in which dysfunction of neuroactive metabolites has been implicated in the pathophysiology of schizophrenia. Inflammatory molecules such as pro-inflammatory cytokines could enhance the activity of IDO. There are few studies on the expression of IDO levels and its correlation with levels of inflammatory cytokines in first-episode drug-naive patients with schizophrenia. One hundred inpatients (female = 33, male = 67) with first-episode drug-naive schizophrenia entered a 6-week, double-blind, randomized, placebo-controlled clinical trial. All individuals were assigned celecoxib or placebo combined with risperidone. Serum levels of IDO and six inflammatory cytokines (IL-1β, IL-6, TNF-α IL-17, IL-4, and INF-γ) were measured. The Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of psychotic symptoms. Compared to healthy subjects, patients had significantly elevated levels of IDO and six cytokines at baseline. Over the 6-week treatment period, the decrease in the levels of IDO and TNF-α and the improvement in the PANSS total score, positive scores, and negative scores in the celecoxib group were significantly greater than in the placebo group. There was a significantly positive correlation between IDO levels and the PANSS negative scores and between IDO levels and TNF-α and IFN-γ levels in the celecoxib group. These findings showed abnormal expression of IDO levels which correlated with negative symptoms and pro-inflammatory cytokine levels in patients with first-episode drug-naive schizophrenia, suggesting the important role of IDO in the pathological mechanism of schizophrenia. Registration number: ChiCTR2000041403.

Indexed as

CytokinesIndoleamine-Pyrrole 2,3,-DioxygenaseSchizophreniaCelecoxibFemaleHumansMaleRisperidoneCelecoxibCytokinesIndoleamine-Pyrrole 2,3,-DioxygenaseRisperidone

Identifiers

PMID34802039
PMCPMC8606005
OpenAlexW3216075323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.